Johnson & Johnson (JNJ) Tops Q4 EPS by 4c, Offers FY21 Guidance

January 26, 2021 6:38 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $1.86, $0.04 better than the analyst estimate of $1.82. Revenue for the quarter came in at $22.5 billion versus the consensus estimate of $21.67 billion.


Johnson & Johnson sees FY2021 EPS of $9.40-$9.60, versus the consensus of $8.99. Johnson & Johnson sees FY2021 revenue of $90.5-91.7 billion, versus the consensus of $89 billion.

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

($ in Billions, except EPS)January 2021

Adjusted Operational Sales1,2

Change vs. Prior Year

8.0% - 9.5%

Operational Sales2

Change vs. Prior Year

$88.8B - $90.0B

7.5% – 9.0%

Estimated Reported Sales3

Change vs. Prior Year

$90.5B - $91.7B

9.5% – 11.0%

Adjusted Operational EPS (Diluted)2,4

Change vs. Prior Year

$9.25 - $9.45

15.2% - 17.7%

Adjusted EPS (Diluted)3,4

Change vs. Prior Year

$9.40 - $9.60

17.1% - 19.6%

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance, Hot Earnings, Hot Guidance

Related Entities

Earnings, Definitive Agreement